Back to Search
Start Over
BofA sees Apogee with 'best-in-class drug' potential, starts with a Buy
- Source :
- The Fly. May 10, 2024
- Publication Year :
- 2024
-
Abstract
- As previously reported, BofA analyst Geoff Meacham initiated coverage of Apogee Therapeutics with a Buy rating and $80 price target. The clinical-stage biotechnology company is developing long-acting biologics for the [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.793346342